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Growing evidence supports a role for mitochondrial ironmetabolism in the pathophysiology
of neurodegenerative disorders such as Friedreich ataxia (FRDA) and Parkinson disease
(PD) as well as in the motor and cognitive decline associated with the aging process. Iron–
sulfur enzyme deﬁcits and regional iron accumulation have been observed in each of these
conditions. In spite of signiﬁcant etiological, clinical and pathological differences that exist
between FRDA and PD, it is possible that defects inmitochondrial iron–sulfur clusters (ISCs)
biogenesis represent a common underlying mechanism leading to abnormal intracellular
iron distribution with mitochondrial iron accumulation, oxidative phosphorylation deﬁcits
and oxidative stress in susceptible cells and speciﬁc regions of the nervous system.
Moreover, a similar mechanism may contribute to the age-dependent iron accumulation
that occurs in certain brain regions such as the globus pallidus and the substantia nigra.
Targeting chelatable iron and reactive oxygen species appear as possible therapeutic
options for FRDA and PD, and possibly other age-related neurodegenerative conditions.
However, new technology to interrogate ISC synthesis in humans is needed to (i) assess
howdefects in this pathway contribute to the natural history of neurodegenerative disorders
and (ii) develop treatments to correct those defects early in the disease process, before
they cause irreversible neuronal cell damage.
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THE NATURAL HISTORY OF NEURODEGENERATIVE DISEASE
Althoughneurodegenerative disorders canpresent at different ages
and with a broad variety of symptoms, their natural histories can
be recapitulated by a few common steps (Figure 1): Normally
developed and overall healthy neuronal cells are exposed to an
insult that initiates the neurodegenerative process; this leads to
progressive neuronal cell dysfunction and death, which ultimately
leads to clinical signs and symptoms of neurological impairment.
However, each of these common steps is inﬂuenced by different
disease-speciﬁc factors. The initiating insult can be genetically-
determined or environmentally-determined or result from a
combination of both genetic and environmental factors. In addi-
tion, for many neurodegenerative disorders aging is a consistently
important risk factor (Zecca et al., 2004b). The neurodegener-
ative process is often neuron-type speciﬁc–for example, motor
neurons are exquisitely affected in amyotrophic lateral sclerosis,
sensory neurons in Friedreich ataxia (FRDA), and dopaminergic
neurons in Parkinson disease (PD) (Koeppen, 2011; Oshiro et al.,
2011). In all cases, the neurodegenerative process is relentlessly
progressive and there is a threshold for neurological manifesta-
tions, meaning that a critical mass of affected neuronal cells will
have to become dysfunctional and/or die in order for clinical signs
and symptoms to become apparent. The rate of progression and
the threshold may vary depending on the cell type and respective
brain region affected as well as additional factors that may inﬂu-
ence disease severity (e.g., the presence of concomitant cardiac
insufﬁciency and skeletalmuscle weakness in FRDA). Importantly,
before the threshold is reached there is a pre-symptomatic
period during which the degenerative process is already
advancing.
By plotting disease progression as a function of age with an
arbitrary threshold for appearance of clinical signs and symp-
toms we can deﬁne three main modalities in the natural history
of neurodegenerative disease (Figure 2). In most individuals
there are slowly progressing, age-related degenerative changes that
become clinically apparent only at an advanced age, manifest-
ing as a decline in motor and cognitive performance after the
7th or 8th decade of life. In addition, there are conditions in
which neurodegeneration occurs at a much faster pace with onset
around the 6th,5th, or 4th decade or life, and others in which
onset is much earlier, in the 2nd or even the 1st decade of life
(Figure 2).
Below we will address the question as to whether and how
defects in mitochondrial iron metabolism may contribute to
these clinical scenarios. Indeed, there are at least two condi-
tions, FRDA and PD, that provide paradigms for the link between
mitochondrial iron dysfunction and, respectively, early-onset
and late-onset neurodegeneration (Zecca et al., 2004a; Koep-
pen et al., 2007; Koeppen, 2011) [reviewed in (Horowitz and
Greenamyre, 2010; Oshiro et al., 2011; Vaubel and Isaya, 2013)].
Table 1 summarizes published evidence which together sug-
gests that FRDA and PD share certain common aspects, also
observed in the aging brain. These aspects include (i) regional
iron accumulation in speciﬁc regions of the central and/or
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FIGURE 1 | Flow-chart representation of the steps and factors involved
in the natural history of neurodegenerative disorders. See text for
details.
FIGURE 2 | Graphic representation of the three main modalities in the
natural history of neurodegenerative disease. The rate of
neurodegenerative disease progression is plotted as a function of age with
an arbitrary threshold for appearance of clinical signs and symptoms. The
plots show typical rates of progression for old age-related, late-onset and
early-onset neurodegenerative disorders. The portion of each plot below the
threshold represents the pre-symptomatic period during which the
degenerative process is already active. FRDA, Friedreich ataxia; PD,
Parkinson disease.
peripheral nervous systems (Zecca et al., 1996; Bartzokis et al.,
2004; Boddaert et al., 2007; Oakley et al., 2007; Koeppen, 2011);
(ii) cellular iron re-distribution within affected cell types that
may result inmitochondrial iron accumulation and iron-catalyzed
Fenton chemistry (Zecca et al., 2004a; Whitnall et al., 2008; Mas-
troberardino et al., 2009); and (iii) the presence of iron–sulfur
enzyme deﬁcits (Rotig et al., 1997; Longo et al., 1999; Betarbet
et al., 2000) [reviewed in (Xu et al., 2010; Gille and Reichmann,
2011; Vaubel and Isaya, 2013; Table 1)]. This evidence supports
the view that a common underlying mechanism involving iron
metabolism–namely, defects in the biogenesis of mitochondrial
iron–sulfur clusters (ISCs) and related enzymes–contributes to
FRDA, PD and the aging process, in spite of these three conditions
being clinically, pathologically and etiologically very different from
one another. Several excellent recent review articles recapitu-
late the current understanding of the molecules and mechanisms
involved in ISC synthesis as well as the roles of iron dysregulation
in the pathophysiology of FRDA, PD, and the aging process. Here
we will review and discuss primarily the roles of ISC dysfunction
in these conditions.
IRON–SULFUR CLUSTER SYNTHESIS AND
NEURODEGENERATIVE DISEASE
Mitochondria across eukaryotes contain a machinery that is
responsible for the biogenesis of ISC inside mitochondria (Schilke
et al., 1999; Muhlenhoff et al., 2002), and that also somehow reg-
ulates the assembly of ISC in other cellular compartments (Kispal
et al., 1999; Gerber et al., 2004; Pondarre et al., 2006; Martelli
et al., 2007). ISC-dependent enzymes are present in the mito-
chondria, the cytoplasm and the nucleus where they participate
in such processes as the citric acid cycle and the electron transport
chain, ribosome biogenesis, and nuclear DNA synthesis and repair
amongothers [reviewed in (Ye andRouault, 2010; Lill et al., 2012)].
The coremachinery that catalyzes the initial step in ISCassembly in
the mitochondrial matrix consists of cysteine desulfurase (NFS1),
a cysteine desulfurase that generates elemental sulfur; frataxin, an
iron-binding protein that provides elemental iron and also stimu-
lates NFS1 activity; and scaffold protein (ISCU), a scaffold protein
upon which [2Fe–2S] and [4Fe–4S] clusters are initially assembled
before being transferred to the appropriate enzymes [reviewed in
(Ye and Rouault, 2010; Lill et al., 2012; Vaubel and Isaya, 2013)].
When this process functions normally, vital enzyme activities are
maintained throughout the cell, iron-catalyzed oxidative damage
is limited, and there is a balance between cellular iron uptake and
mitochondrial iron utilization (Figure 3).
The consequences of defects in ISC synthesis have been exten-
sively studied in a number of S. cerevisiae mutants in which
this process was genetically impaired [although only partially
since a complete loss of ISC synthesis is not compatible with
life across eukaryotes (Cossee et al., 2000; Lill and Kispal, 2000;
Kispal et al., 2005)]. These mutants have consistently shown a
series of key mitochondrial and cellular features. Within mito-
chondria, reduced formation of ISC leads to an increase in the
fraction of labile iron that leads to higher rates of Fenton chem-
istry resulting in loss of mitochondrial DNA integrity and overall
loss of oxidative phosphorylation (Knight et al., 1998; Li et al.,
1999; Karthikeyan et al., 2003). Simultaneously, the cell responds
to reduced mitochondrial ISC synthesis with a rapid increase in
cellular iron uptake and intracellular re-distribution of iron that
is depleted in the cytoplasm but continues to accumulate in mito-
chondria until it precipitates out of solution as an amorphous
mineral (Babcock et al., 1997; Knight et al., 1998; Li et al., 1999;
Chen et al., 2004). These features hold true in multicellular organ-
isms including humans as we will see in the speciﬁc cases of FRDA
and PD.
FRIEDREICH ATAXIA
FRDA is an autosomal recessive disease and the most common
genetically-determined ataxia that affects approximately 1:40,000
individuals in the Caucasian population [for recent reviews see
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Table 1 | Indicators of mitochondrial Fe–S cluster dysfunction in FRDA, PD, and aging.
FRDA* PD** Aging***
Regional iron accumulation Dorsal root ganglia,
Nucleus dentatus, Heart
Substantia nigra Globus pallidus, Substantia
nigra, Skeletal muscle
Cellular iron redistribution,
mitochondrial iron accumulation, HO•
+ + +
Fe–S enzyme deﬁcits Generalized Complex I Mitochondrial aconitase
*(Rotig et al., 1997; Koeppen, 2011); **(Horowitz and Greenamyre, 2010); ***(Bota et al., 2002; Xu et al., 2010).
FIGURE 3 | Molecular components involved in the initial step of
mitochondrial ISC synthesis and their biological roles. When
mitochondrial ISC synthesis functions normally, vital enzyme activities are
maintained throughout the cell, iron-catalyzed oxidative damage is limited,
and there is a balance between iron uptake and iron utilization. See text for
additional details. NFS1, cysteine desulfurase; ISD11, adaptor protein
required for NFS1 stability; ISCU, scaffold protein; I, II, III, respiratory chain
complexes I, II, and III; Aco, mitochondrial aconitase; mtDNA, mitochondrial
DNA; nDNA, nuclear DNA.
(Pandolfo, 2009; Koeppen, 2011)]. Patients are healthy at birth
and remain largely asymptomatic for the ﬁrst 5–10 years of life
but then begin to present progressive neurological impairment
and additional problems including cardiac disease, muscle weak-
ness, skeletal deformities, vision and hearing loss, and diabetes.
Patients eventually become wheelchair-bound and most often
die of cardiac failure in the 2nd or 3rd decade of life. Certain
regions of the central (cerebellum and spinal cord) and peripheral
(dorsal root ganglia and their nerves) nervous systems as well as
the heart, skeletal muscles, skeleton, and endocrine pancreas are
affected (Koeppen, 2011). This early-onset, very dramatic clin-
ical and pathological progression results in most patients from
reduced levels of a mitochondrial iron-binding protein called
frataxin (Campuzano et al., 1996). The biochemical properties of
frataxin include the ability to bind iron, the ability to donate iron
to other iron-binding proteins, and the ability to oligomerize, store
iron and control iron redox chemistry [reviewed in (Bencze et al.,
2006)]. Through these properties, frataxin plays key roles in differ-
ent iron-dependent pathways (primarily, although not exclusively,
ISC synthesis) and is therefore critical for mitochondrial iron
metabolism and overall cellular iron homeostasis and antioxidant
protection [reviewed in (Wilson, 2006; Vaubel and Isaya, 2013)].
MITOCHONDRIAL AND OTHER CELLULAR CONSEQUECES OF FRATAXIN
DEFICIENCY
Reduced levels of frataxin in FRDA mouse models and human
patients result in defects in ISC enzymes even before mitochon-
drial iron accumulation becomes detectable (Puccio et al., 2001;
Stehling et al., 2004). However, iron dysregulation is an early
effect of frataxin depletion, which increases the fraction of labile
redox-active iron inside mitochondria (Wong et al., 1999) lead-
ing to progressive accumulation of oxidative damage (Whitnall
et al., 2012). In addition, in mouse heart the lack of frataxin
results in gene expression changes leading to down-regulation of
proteins involved in mitochondrial ISC synthesis, heme synthe-
sis, and iron storage as well as proteins involved in cellular and
mitochondrial iron uptake, which collectively lead to intracellular
iron redistrbution and progressive mitochondrial iron accumu-
lation (Huang et al., 2009). All of these effects ultimately result
in progressive impairment of energy metabolism and accumula-
tion of oxidative damage [reviewed in (Pandolfo, 2006; Wilson,
2006)]. There are also additional changes outside of mitochon-
dria affecting pathways involved in antioxidant, metabolic, and
inﬂammatory responses, which are believed to contribute to dis-
ease progression [(Pianese et al., 2002; Coppola et al., 2009; Lu
et al., 2009; Paupe et al., 2009; Sparaco et al., 2009; Wagner et al.,
2012); reviewed in (Pandolfo, 2012)].
PARKINSON DISEASE
PD is a common neurodegenerative disease affecting∼1:800 indi-
viduals between the 5th and 7th decade of life with a median
survival from diagnosis of about 15 years. The degenerative pro-
cess exquisitely affects dopaminergic neurons in the substantia
nigra and clinically leads to progressive motor deﬁcits including
bradykinesia, rigidity, resting tremor, and postural instability as
well as a variety of non-motor symptoms in the late stages of
the disease. Age is the main risk factor for PD although suscep-
tibility genes and environmental toxins are also implicated in the
pathophysiology [reviewed in (Lees et al., 2009)].
IRON DYSREGULATION CONTRIBUTES TO PD
A signiﬁcant body of data [reviewed in (Mastroberardino et al.,
2009)] supports a role for a defect in ISC synthesis in PD: (i)
mitochondrial impairment and oxidative stress are involved in
the pathophysiology of PD (Greenamyre and Hastings, 2004);
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(ii) partial inhibition of Complex I of the respiratory chain
(which includes several ISC-containing subunits) recapitulates
many features of PD (Betarbet et al., 2000; Przedborski et al.,
2001); (iii) iron levels are increased in the substantia nigra and
within substantia nigra dopaminergic neurons of PD patients
(Berg and Hochstrasser, 2006; Oakley et al., 2007); (iv) iron chela-
tion protects substantia nigra neurons in animal models of PD
(Ben-Shachar et al., 1991; Kaur et al., 2003) as well as PD patients
(Devos et al., 2013). Mastroberardino et al. have described a novel
pathway of iron transport to mitochondria of substantia nigra
dopaminergic neurons involving transferrin and the transferrin
receptor 2 (Mastroberardino et al., 2009). This pathway normally
delivers transferrin-bound iron to mitochondria and to Complex
I of the respiratory chain. In PD, however, there is an induc-
tion of transferrin receptor 2 expression and accumulation of
oxidized transferrin inside mitochondria, which results in the
release of labile ferrous iron from transferrin and the generation
of hydroxyl radicals via Fenton chemistry (Mastroberardino et al.,
2009; Horowitz and Greenamyre, 2010). A concomitant reduction
inmitochondrial ISC synthesis has been postulated (Horowitz and
Greenamyre, 2010), and could probably account for the cascade
of events described above in at least two ways (Figure 4). Early
on, a speciﬁc defect in the synthesis and/or delivery of ISC cofac-
tors needed for Complex I activity could induce the transferring
receptor 2 pathway, thereby triggering the increase in cellular iron
uptake and the ensuing mitochondrial iron accumulation with
iron-catalyzed oxidative damage. Under these conditions, the need
to handle redox-active iron could likely make the ISC assembly
machinery especially susceptible to oxidative damage fromradicals
generated via Fenton chemistry. Thus, progressive accumulation
of oxidative damage could later lead to a more generalized ISC
synthesis defect further enhancing cellular iron dysregulation in
dopaminergic neurons (Figure 4).
IRON ACCUMULATION IN THE AGING BRAIN
So far we have reviewed FRDA, where a defect in ISC synthe-
sis is clearly associated with disease pathogenesis early on in the
disease process, and PD, where a defect in ISC synthesis may
be involved at both an early and a late stage of disease pro-
gression. Could a reduction in ISC synthesis also contribute to
age-dependent iron accumulation in the brain? Iron accumulates
in speciﬁc regions of the brain (primarily the globus pallidus
and the substantia nigra) in an age-dependent manner, and
iron-induced oxidative damage is implicated in age-dependent
neuronal loss (Bartzokis et al., 2004; Zecca et al., 2004a,b; Xu
et al., 2010). Moreover, loss of mitochondrial aconitase activ-
ity, an enzyme of the citric acid cycle that requires a [4Fe–4S]
cluster for function and stability (Bulteau et al., 2003), is a
marker of aging (Longo et al., 1999; Bota et al., 2002; Bulteau
et al., 2006). Thus, it is possible to once again envision how the
need to handle redox-active iron could subject the ISC assem-
bly machinery to progressive accumulation of oxidative damage.
This could lead to an age-dependent decline in ISC synthesis and
loss of critical ISC enzyme activities, with progressive cellular
and mitochondrial iron dysregulation, similar to what we have
discussed above for FRDA and PD. Figure 5 shows a possible
unifying model whereby a continuum of clinical phenotypes
FIGURE 4 | Proposed model for a role of ISC synthesis defects in PD
progression. See text for details. Tf, transferrin; TfR2, transferrin receptor;
other abbreviations are as in the legend for Figure 3.
FIGURE 5 | A spectrum of clinical phenotypes may be linked to ISC
synthesis defects. ISC synthesis defects of decreasing severity lead to a
variety of clinical phenotypes ranging from embryonic lethality to increased
predisposition to age-related disorders.
are associated with ISC synthesis defects of varying degree. We
hypothesize that genetically-determined or acquired (environ-
mental or age-dependent) defects in ISC synthesis contributemore
prominently to human disease than it is currently appreciated.
Indeed, age-dependent accumulation of iron and iron-catalyzed
oxidative damage have been implicated not only in FRDA and
PD but also Alzheimer’s disease (Zecca et al., 2004b), atheroscle-
rosis (Zacharski et al., 2000), and heart disease (Wood, 2004).
As the aging population continues to expand, it is likely that
the prevalence of conditions associated with age-dependent iron
accumulation will also increase.
IRON CHELATION FOR TREATMENTS OF FRDA AND PD
As we have seen, eukaryotic cells require mitochondrial ISC
synthesis not only to ensure the biogenesis and function of a
large number of ISC-dependent enzymes but also to maintain
a balance between iron uptake and iron utilization (Figure 3).
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While there are no approaches as yet available to correct defects
in ISC synthesis directly, targeting chelatable iron represents a
reasonable approach to limit the consequences of these defects,
primarily mitochondrial iron overload and iron-catalyzed Fen-
ton chemistry. Iron chelation is widely used to reduce iron
deposition in the organs of patients affected by disorders char-
acterized by global iron overload (e.g., hemochromatosis; Barton,
2007; Flaten et al., 2012). However, in the case of FRDA or PD,
the regional nature of the iron accumulation and the abnormal
iron distribution within the affected cell types have suggested
the need for agents able to appropriately “relocate” iron while
at the same time limiting its participation in radical-generating
reactions (Boddaert et al., 2007). Deferiprone, a chelator used
for treating iron overload, has been shown to possess this iron
“relocating” ability by scavenging labile iron from mitochondria
and delivering it to cytoplasmic and extracellular apotransfer-
rin. In cells derived from FRDA patients, deferiprone decreased
the levels of mitochondrial labile iron and also limited oxida-
tive damage (Kakhlon et al. 2008, 2010), presumably by limit-
ing iron-catalyzed Fenton chemistry (Kontoghiorghes, 2009). A
six-month open-label single-arm study with deferiprone, admin-
istered together with the antioxidant idebenone, was initially
conducted in nine adolescents affected by FRDA. By use of mag-
netic resonance imaging, selective iron removal was observed
in the nucleus dentatus of the cerebellum in all patients, while
improved neuromotor function was observed in the youngest
patients (Boddaert et al., 2007). An 11 month open-labeled study
in 20 FRDA patients conﬁrmed that deferiprone and idebenone
combined could improve iron deposits in the dentate nucleus
with a stabilizing effect on certain neurological parameters (in
addition to signiﬁcantly improved heart hypertrophy parameters;
Velasco-Sanchez et al., 2011). However, a subsequent double-
blind, randomized placebo-controlled phase 2 trial showed a
worsening of ataxia with doses of deferiprone ≥40 mg/Kg/day.
In the same study, there were no signiﬁcant changes in ataxia
with lower doses of deferiprone, though improvements in pos-
ture, gait, and kinetic function were noted in some patients, and
a signiﬁcant decrease in left ventricular mass in most patients
[reviewed in (Wilson, 2012; Pandolfo and Hausmann, 2013)].
These dose-dependent effects may be explained by a report
that concentrations of deferiprone ≥50 μM in cultured cells
induced iron depletion rather than redistribution, with dele-
terious effects on ISC enzyme activities and even on frataxin
levels (Pandolfo and Hausmann, 2013). A moderate iron chela-
tion regimen that did not alter systemic iron levels was recently
tested in a pilot clinical study of deferiprone in early-stage PD
patients; this regimen was shown to improve iron deposits in
the substantia nigra as well as motor parameters of disease
progression (Devos et al., 2013). These studies underscore the
importance of identifying iron chelation modalities that can
correct iron distribution within affected neuronal cells with-
out inducing deleterious global changes in iron metabolism,
including changes in the expression of frataxin and other mito-
chondrial proteins involved in ISC synthesis. Better understanding
of disease natural history and ability to intervene in the pre-
symptomatic phase may also be critical to achieve effective
treatments.
CONCLUSION AND FUTURE DIRECTIONS
The best characterized human condition linked to abnormal
mitochondrial ISC synthesis is FRDA. Tissue-speciﬁc defects in
mitochondrial ISC synthesis have more recently been identiﬁed in
patients with isolated myopathy (Mochel et al., 2008; Olsson et al.,
2008) or sideroblastic anemia (Camaschella et al., 2007), which are
linked to mutations in the scaffold ISCU and the enzyme glutare-
doxin 5, respectively. The combination of genetic and clinical
heterogeneity (as illustrated by these three disorders) can make
inherited defects in ISC synthesis difﬁcult to recognize, and it is
likely that their combined prevalence is underestimated. It is also
possible that tissue-speciﬁc decline in ISC synthesis is implicated
in the iron accumulation that occurs not only in PD and the aging
brain (Zecca et al., 2004b) but also the vasculature (Zacharski et al.,
2000) and the heart (Wood, 2004) during aging. Another possi-
ble link to aging is suggested by a recent report that impaired ISC
biogenesis leads to nuclear genome instability (Veatch et al., 2009).
These interesting links remain largely unexplored due to the lack of
suitable technology. The activities of natural (e.g., mitochondrial
aconitase or succinate dehydrogenase; Foury, 1999; Mochel et al.,
2008) or artiﬁcial (Hoff et al., 2009a,b) ISC-containing enzymes
are currently used as measures of ISC synthesis. One limitation is
that these activities lay downstream of the initial and rate-limiting
step in ISC synthesis (i.e., the assembly of [2Fe–2S] clusters on
ISC scaffolds). In addition, they can be inﬂuenced by factors (e.g.,
oxidative stress) independent of the actual rate of ISC synthesis.
In essence, technology to interrogate ISC synthesis directly in vivo,
for translational and clinical research studies, is currently lacking.
Development of such technology will open the possibility to (i)
assess the extent to which this pathway contributes to neurodegen-
erative disease and age-related disorders, and (ii) develop strategies
to correct primary or secondary functional deﬁcits. Given the
role played by ISC synthesis in the maintenance of many vital
enzymes and iron homeostasis, as well as the prevention of iron-
catalyzed oxidative stress, we predict that this technology will have
important biomedical applications.
ACKNOWLEDGMENT
Grazia Isaya is supported by a grant from the National Institutes
of Health/National Institute on Aging (AG15709).
REFERENCES
Babcock, M., de Silva, D., Oaks, R., Davis-Kaplan, S., Jiralerspong, S., Mon-
termini, L., et al. (1997). Regulation of mitochondrial iron accumulation
by Yfh1p, a putative homolog of frataxin. Science 276, 1709–1712. doi:
10.1126/science.276.5319.1709
Barton, J. C. (2007). Chelation therapy for iron overload. Curr. Gastroenterol. Rep.
9, 74–82. doi: 10.1007/s11894-008-0024-9
Bartzokis, G., Tishler, T. A., Shin, I. S., Lu, P. H., and Cummings, J. L. (2004). Brain
ferritin iron as a risk factor for age at onset in neurodegenerative diseases. Ann.
N. Y. Acad. Sci. 1012, 224–236. doi: 10.1196/annals.1306.019
Bencze, K. Z., Kondapalli, K. C., Cook, J. D., McMahon, S., Millan-Pacheco, C.,
Pastor,N., et al. (2006). The structure and function of frataxin.Crit. Rev. Biochem.
Mol. Biol. 41, 269–291. doi: 10.1080/10409230600846058
Ben-Shachar, D., Eshel, G., Finberg, J. P., and Youdim, M. B. (1991). The iron
chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degen-
eration of nigrostriatal dopamine neurons. J. Neurochem. 56, 1441–1444. doi:
10.1111/j.1471-4159.1991.tb11444.x
Berg, D., andHochstrasser, H. (2006). Ironmetabolism in Parkinsonian syndromes.
Mov. Disord. 21, 1299–1310. doi: 10.1002/mds.21020
www.frontiersin.org March 2014 | Volume 5 | Article 29 | 5
Isaya Iron–sulfur cluster synthesis in neurodegenerative disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V.,
Greenamyre, J. T., et al. (2000). Chronic systemic pesticide exposure reproduces
features of Parkinson’s disease. Nat. Neurosci. 3, 1301–1306. doi: 10.1038/81834
Boddaert, N., Le Quan Sang, K. H., Rotig, A., Leroy-Willig, A., Gallet, S., Brunelle,
F., et al. (2007). Selective iron chelation in Friedreich ataxia: biologic and clinical
implications. Blood 110, 401–408. doi: 10.1182/blood-2006-12-065433
Bota, D. A., Van Remmen, H., and Davies, K. J. (2002). Modulation of Lon protease
activity and aconitase turnover during aging and oxidative stress. FEBS Lett. 532,
103–106. doi: 10.1016/S0014-5793(02)03638-4
Bulteau, A. L., Ikeda-Saito, M., and Szweda, L. I. (2003). Redox-dependent modula-
tion of aconitase activity in intact mitochondria. Biochemistry 42, 14846–14855.
doi: 10.1021/bi0353979
Bulteau,A. L., Szweda, L. I., and Friguet, B. (2006). Mitochondrial protein oxidation
and degradation in response to oxidative stress and aging. Exp. Gerontol. 41,
653–657. doi: 10.1016/j.exger.2006.03.013
Camaschella, C., Campanella, A., De Falco, L., Boschetto, L.,Merlini, R., Silvestri, L.,
et al. (2007). The human counterpart of zebraﬁsh shiraz shows sideroblastic-like
microcytic anemia and iron overload. Blood 110, 1353–1358. doi: 10.1182/blood-
2007-02-072520
Campuzano, V., Montermini, L., Molto, M. D., Pianese, L., Cossee, M., Caval-
canti, F., et al. (1996). Friedreich’s ataxia: autosomal recessive disease caused
by an intronic GAA triplet repeat expansion. Science 271, 1423–1427. doi:
10.1126/science.271.5254.1423
Chen, O. S., Crisp, R. J., Valachovic, M., Bard, M., Winge, D. R., Kaplan, J., et al.
(2004). Transcription of the yeast iron regulon does not respond directly to iron
but rather to iron-sulfur cluster biosynthesis. J. Biol. Chem. 279, 29513–29518.
doi: 10.1074/jbc.M403209200
Coppola, G., Marmolino, D., Lu, D., Wang, Q., Cnop, M., Rai, M., et al.
(2009). Functional genomic analysis of frataxin deﬁciency reveals tissue-speciﬁc
alterations and identiﬁes the PPARgamma pathway as a therapeutic target
in Friedreich’s ataxia. Hum. Mol. Genet. 18, 2452–2461. doi: 10.1093/hmg/
ddp183
Cossee, M., Puccio, H., Gansmuller, A., Koutnikova, H., Dierich, A., LeMeur, M.,
et al. (2000). Inactivation of the Friedreich ataxia mouse gene leads to early
embryonic lethality without iron accumulation.Hum. Mol. Genet. 9, 1219–12126.
doi: 10.1093/hmg/9.8.1219
Devos, D., Moreau, C., Devedjian, J. C., Kluza, J., Laloux, C., Jonneaux, A., et al.
(2013). Targeting chelatable iron as a therapeutic modality in Parkinson’s disease.
Antioxid. Redox Signal. doi: 10.1089/ars.2013.5593 [Epub ahead of print].
Flaten, T. P., Aaseth, J., Andersen, O., and Kontoghiorghes, G. J. (2012). Iron mobi-
lization using chelation and phlebotomy. J. Trace Elem. Med. Biol. 26, 127–130.
doi: 10.1016/j.jtemb.2012.03.009
Foury, F. (1999). Low iron concentration and aconitase deﬁciency in a yeast
frataxinhomologuedeﬁcient strain. FEBSLett. 456, 281–284. doi: 10.1016/S0014-
5793(99)00961-8
Gerber, J., Neumann, K., Prohl, C., Muhlenhoff, U., and Lill, R. (2004). The
yeast scaffold proteins Isu1p and Isu2p are required inside mitochondria for
maturation of cytosolic Fe/S proteins. Mol. Cell. Biol. 24, 4848–4857. doi:
10.1128/MCB.24.11.4848-4857.2004
Gille, G., and Reichmann, H. (2011). Iron-dependent functions of mitochondria–
relation to neurodegeneration. J. Neural Transm. 118, 349–359. doi:
10.1007/s00702-010-0503-7
Greenamyre, J. T., and Hastings, T. G. (2004). Biomedicine. Parkinson’s–divergent
causes, convergent mechanisms. Science 304, 1120–1122. doi: 10.1126/sci-
ence.1098966
Hoff, K. G., Culler, S. J., Nguyen, P. Q., McGuire, R. M., Silberg, J. J., Smolke, C.
D., et al. (2009a). In vivo ﬂuorescent detection of Fe-S clusters coordinated by
human GRX2. Chem. Biol. 16, 1299–1308. doi: 10.1016/j.chembiol.2009.11.011
Hoff, K. G., Goodlitt, R., Li, R., Smolke, C. D., and Silberg, J. J. (2009b). Fluores-
cence detection of a protein-bound 2Fe2S cluster. Chembiochem 10, 667–670. doi:
10.1002/cbic.200800747
Horowitz, M. P., and Greenamyre, J. T. (2010). Mitochondrial iron metabolism and
its role in neurodegeneration. J. Alzheimers Dis. 20(Suppl. 2), S551–S568. doi:
10.3233/JAD-2010-100354
Huang, M. L., Becker, E. M., Whitnall, M., Rahmanto, Y. S., Ponka, P., Richardson,
D. R., et al. (2009). Elucidation of the mechanism of mitochondrial iron loading
in Friedreich’s ataxia by analysis of a mouse mutant. Proc. Natl. Acad. Sci. US.A.
106, 16381–16386. doi: 10.1073/pnas.0906784106
Kakhlon, O., Breuer,W.,Munnich, A., and Cabantchik, Z. I. (2010). Iron redistribu-
tion as a therapeutic strategy for treating diseases of localized iron accumulation.
Can. J. Physiol. Pharmacol. 88, 187–196. doi: 10.1139/Y09-128
Kakhlon, O., Manning, H., Breuer, W., Melamed-Book, N., Lu, C., Cortopassi,
G., et al. (2008). Cell functions impaired by frataxin deﬁciency are restored by
drug-mediated iron relocation. Blood 112, 5219–5227. doi: 10.1182/blood-2008-
06-161919
Karthikeyan, G., Santos, J. H., Graziewicz, M. A., Copeland, W. C., Isaya, G.,
van Houten, B., et al. (2003). Reduction in frataxin causes progressive accu-
mulation of mitochondrial damage. Hum. Mol. Genet. 12, 3331–3342. doi:
10.1093/hmg/ddg349
Kaur, D., Yantiri, F., Rajagopalan, S., Kumar, J., Mo, J. Q., Boonplueang, R., et al.
(2003). Genetic or pharmacological iron chelation prevents MPTP-induced neu-
rotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 37, 899–909.
doi: 10.1016/S0896-6273(03)00126-0
Kispal, G., Csere, P., Prohl, C., and Lill, R. (1999). The mitochondrial proteins
Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins. EMBO J.
18, 3981–3989. doi: 10.1093/emboj/18.14.3981
Kispal, G., Sipos, K., Lange, H., Fekete, Z., Bedekovics, T., Janaky, T., et al. (2005).
Biogenesis of cytosolic ribosomes requires the essential iron-sulphurproteinRli1p
and mitochondria. EMBO J. 24, 589–598. doi: 10.1038/sj.emboj.7600541
Knight, S. A., Sepuri, N. B., Pain, D., and Dancis, A. (1998). Mt-Hsp70
homolog, Ssc2p, required formaturation of yeast frataxin andmitochondrial iron
homeostasis. J. Biol. Chem. 273, 18389–18393. doi: 10.1074/jbc.273.29.18389
Koeppen, A. H. (2011). Friedreich’s ataxia: pathology, pathogenesis, and molecular
genetics. J. Neurol. Sci. 303, 1–12. doi: 10.1016/j.jns.2011.01.010
Koeppen, A. H., Michael, S. C., Knutson, M. D., Haile, D. J., Qian, J., Levi, S., et al.
(2007). The dentate nucleus in Friedreich’s ataxia: the role of iron-responsive
proteins. Acta Neuropathol. 114, 163–173. doi: 10.1007/s00401-007-0220-y
Kontoghiorghes, G. J. (2009). Prospects for introducing deferiprone as potent
pharmaceutical antioxidant. Front. Biosci. (Elite Ed.) 1:161–178.
Lees, A. J., Hardy, J., and Revesz, T. (2009). Parkinson’s disease. Lancet 373, 2055–
2066. doi: 10.1016/S0140-6736(09)60492-X
Li, J., Kogan, M., Knight, S. A., Pain, D., and Dancis, A. (1999). Yeast mito-
chondrial protein, Nfs1p, coordinately regulates iron-sulfur cluster proteins,
cellular iron uptake, and iron distribution. J. Biol. Chem. 274, 33025–33034.
doi: 10.1074/jbc.274.46.33025
Lill, R., Hoffmann, B., Molik, S., Pierik, A. J., Rietzschel, N., Stehling, O.,
et al. (2012). The role of mitochondria in cellular iron-sulfur protein bio-
genesis and iron metabolism. Biochim. Biophys. Acta 1823, 1491–1508. doi:
10.1016/j.bbamcr.2012.05.009
Lill, R., and Kispal, G. (2000). Maturation of cellular Fe-S proteins: an essential
function of mitochondria.Trends. Biochem. Sci. 25, 352–356. doi: 10.1016/S0968-
0004(00)01589-9
Longo, V. D., Liou, L. L., Valentine, J. S., and Gralla, E. B. (1999). Mitochondrial
superoxide decreases yeast survival in stationary phase. Arch. Biochem. Biophys.
365, 131–142. doi: 10.1006/abbi.1999.1158
Lu,C., Schoenfeld, R., Shan,Y., Tsai,H. J.,Hammock, B., Cortopassi,G., et al. (2009).
Frataxin deﬁciency induces Schwann cell inﬂammation and death. Biochim.
Biophys. Acta 1792, 1052–1061. doi: 10.1016/j.bbadis.2009.07.011
Martelli, A., Wattenhofer-Donze, M., Schmucker, S., Bouvet, S., Reutenauer, L.,
Puccio, H., et al. (2007). Frataxin is essential for extramitochondrial Fe-S clus-
ter proteins in mammalian tissues. Hum. Mol. Genet. 16, 2651–2658. doi:
10.1093/hmg/ddm163
Mastroberardino, P. G., Hoffman, E. K., Horowitz, M. P., Betarbet, R., Taylor, G.,
Cheng, D., et al. (2009). A novel transferrin/TfR2-mediated mitochondrial iron
transport system is disrupted in Parkinson’s disease. Neurobiol. Dis. 34, 417–431.
doi: 10.1016/j.nbd.2009.02.009
Mochel, F., Knight, M. A., Tong, W. H., Hernandez, D., Ayyad, K., Taivassalo, T.,
et al. (2008). Splice mutation in the iron-sulfur cluster scaffold protein ISCU
causes myopathy with exercise intolerance. Am. J. Hum. Genet. 82, 652–660. doi:
10.1016/j.ajhg.2007.12.012
Muhlenhoff, U., Richter, N., Gerber, J., and Lill, R. (2002). Characterization of iron-
sulfur protein assembly in isolated mitochondria: a requirement for ATP, NADH
and reduced iron. J. Biol. Chem. 277, 29810–29816. doi: 10.1074/jbc.M204675200
Oakley,A. E., Collingwood, J. F.,Dobson, J., Love,G., Perrott,H. R., Edwardson, J.A.,
et al. (2007). Individual dopaminergic neurons show raised iron levels in Parkin-
son disease. Neurology 68, 1820–1825. doi: 10.1212/01.wnl.0000262033.01945.9a
Frontiers in Pharmacology | Drug Metabolism andTransport March 2014 | Volume 5 | Article 29 | 6
Isaya Iron–sulfur cluster synthesis in neurodegenerative disease
Olsson, A., Lind, L., Thornell, L. E., and Holmberg, M. (2008). Myopathy with
lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron
mutation in the ISCU gene resulting in a splicing defect. Hum. Mol. Genet. 17,
1666–1672. doi: 10.1093/hmg/ddn057
Oshiro, S., Morioka, M. S., and Kikuchi, M. (2011). Dysregulation of iron
metabolism in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral
sclerosis. Adv. Pharmacol. Sci. 2011, 1–8.
Pandolfo, M. (2006). Iron and Friedreich ataxia. J. Neural Transm. Suppl. 70,
143–146.
Pandolfo, M. (2009). Friedreich ataxia: the clinical picture. J. Neurol. 256(Suppl. 1),
3–8. doi: 10.1007/s00415-009-1002-3
Pandolfo, M. (2012). Friedreich ataxia: new pathways. J. Child Neurol. 27, 1204–
1211. doi: 10.1177/0883073812448534
Pandolfo, M., and Hausmann, L. (2013). Deferiprone for the treatment of
Friedreich’s ataxia. J. Neurochem. 126(Suppl. 1), 142–146. doi: 10.1111/jnc.12300
Paupe, V., Dassa, E. P., Goncalves, S., Auchere, F., Lonn, M., Holmgren, A.,
et al. (2009). Impaired nuclear Nrf2 translocation undermines the oxidative
stress response in Friedreich ataxia. PLoS ONE 4:e4253. doi: 10.1371/jour-
nal.pone.0004253
Pianese, L., Busino, L., De Biase, I., De Cristofaro, T., Lo Casale, M. S., Giuliano, P.,
et al. (2002). Up-regulation of c-Jun N-terminal kinase pathway in Friedreich’s
ataxia cells. Hum. Mol. Genet. 11, 2989–2996. doi: 10.1093/hmg/11.23.2989
Pondarre, C., Antiochos, B. B., Campagna, D. R., Clarke, S. L., Greer, E. L., Deck, K.
M., et al. (2006). The mitochondrial ATP-binding cassette transporter Abcb7 is
essential inmice and participates in cytosolic iron-sulfur cluster biogenesis. Hum.
Mol. Genet. 15, 953–964. doi: 10.1093/hmg/ddl012
Przedborski, S., Jackson-Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G.,
Miller, R., et al. (2001). The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP): a technical review of its utility and safety. J.
Neurochem. 76, 1265–1274. doi: 10.1046/j.1471-4159.2001.00183.x
Puccio,H., Simon,D., Cossee,M.,Criqui-Filipe, P., Tiziano, F.,Melki, J., et al. (2001).
Mouse models of Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect
and Fe-S enzyme deﬁciency followed by intramitochondrial iron deposits. Nat.
Genet. 27, 181–186. doi: 10.1038/84818
Rotig, A., de Lonlay, P., Chretien, D., Foury, F., Koenig, M., Sidi, D., et al. (1997).
Aconitase andmitochondrial iron-sulphur protein deﬁciency in Friedreich ataxia.
Nat. Genet. 17, 215–217. doi: 10.1038/ng1097-215
Schilke, B., Voisine, C., Beinert, H., and Craig, E. (1999). Evidence for a conserved
system for ironmetabolism in themitochondria of Saccharomyces cerevisiae. Proc.
Natl. Acad. Sci. U.S.A. 96, 10206–10211. doi: 10.1073/pnas.96.18.10206
Sparaco, M., Gaeta, L. M., Santorelli, F. M., Passarelli, C., Tozzi, G., Bertini, E.,
et al. (2009). Friedreich’s ataxia: oxidative stress and cytoskeletal abnormalities.
J. Neurol. Sci. 287, 111–118. doi: 10.1016/j.jns.2009.08.052
Stehling, O., Elsasser, H. P., Bruckel, B., Muhlenhoff, U., and Lill, R. (2004). Iron-
sulfur protein maturation in human cells: evidence for a function of frataxin.
Hum. Mol. Genet. 13, 3007–3015. doi: 10.1093/hmg/ddh324
Vaubel, R. A., and Isaya, G. (2013). Iron-sulfur cluster synthesis, iron homeostasis
and oxidative stress in Friedreich ataxia. Mol. Cell. Neurosci. 55, 50–61. doi:
10.1016/j.mcn.2012.08.003
Veatch, J. R., McMurray, M. A., Nelson, Z. W., and Gottschling, D. E. (2009).
Mitochondrial dysfunction leads to nuclear genome instability via an iron-sulfur
cluster defect. Cell 137, 1247–1258. doi: 10.1016/j.cell.2009.04.014
Velasco-Sanchez, D., Aracil, A., Montero, R., Mas, A., Jimenez, L., O’Callaghan, M.,
et al. (2011). Combined therapy with idebenone and deferiprone in patients with
Friedreich’s ataxia. Cerebellum 10, 1–8. doi: 10.1007/s12311-010-0212-7
Wagner, G. R., Pride, P. M., Babbey, C. M., and Payne, R. M. (2012). Friedreich’s
ataxia reveals a mechanism for coordinate regulation of oxidative metabolism via
feedback inhibition of the SIRT3 deacetylase. Hum. Mol. Genet. 21, 2688–2697.
doi: 10.1093/hmg/dds095
Whitnall, M., Rahmanto, Y. S., Sutak, R., Xu, X., Becker, E. M., Mikhael, M. R.,
et al. (2008). The MCK mouse heart model of Friedreich’s ataxia: alterations in
iron-regulated proteins and cardiac hypertrophy are limited by iron chelation.
Proc. Natl. Acad. Sci. U.S.A. 105, 9757–9762. doi: 10.1073/pnas.0804261105
Whitnall,M., Suryo Rahmanto,Y., Huang,M. L., Saletta, F., Lok,H. C., Gutierrez, L.,
et al. (2012). Identiﬁcation of nonferritin mitochondrial iron deposits in a mouse
model of Friedreich ataxia. Proc. Natl. Acad. Sci. U.S.A. 109, 20590–20595. doi:
10.1073/pnas.1215349109
Wilson, R. B. (2006). Iron dysregulation in Friedreich ataxia. Semin. Pediatr. Neurol.
13, 166–175. doi: 10.1016/j.spen.2006.08.005
Wilson, R. B. (2012). Therapeutic developments in Friedreich ataxia. J. ChildNeurol.
27, 1212–1216. doi: 10.1177/0883073812449691
Wong, A., Yang, J., Cavadini, P., Gellera, C., Lonnerdal, B., Taroni, F., et al. (1999).
The Friedreich’s ataxiamutation confers cellular sensitivity to oxidant stresswhich
is rescued by chelators of iron and calcium and inhibitors of apoptosis.Hum. Mol.
Genet. 8, 425–430. doi: 10.1093/hmg/8.3.425
Wood, R. J. (2004). The iron-heart disease connection: is it dead or just hiding?
Ageing Res. Rev. 3, 355–367. doi: 10.1016/j.arr.2004.04.002
Xu, J.,Marzetti, E., Seo,A. Y., Kim, J. S., Prolla, T. A., Leeuwenburgh, C., et al. (2010).
The emerging role of iron dyshomeostasis in the mitochondrial decay of aging.
Mech. Ageing Dev. 131, 487–493. doi: 10.1016/j.mad.2010.04.007
Ye, H., and Rouault, T. A. (2010). Human iron-sulfur cluster assembly, cellular iron
homeostasis, and disease. Biochemistry 49, 4945–4956. doi: 10.1021/bi1004798
Zacharski, L. R., Chow, B., Lavori, P. W., Howes, P. S., Bell, M. R., DiTommaso, M.
A., et al. (2000). The iron (Fe) and atherosclerosis study (FeAST): a pilot study of
reduction of body iron stores in atherosclerotic peripheral vascular disease. Am.
Heart J. 139, 337–345.
Zecca, L., Shima, T., Stroppolo, A., Goj, C., Battiston, G. A., Gerbasi, R., et al.
(1996). Interaction of neuromelanin and iron in substantia nigra and other areas
of human brain. Neuroscience 73, 407–415. doi: 10.1016/0306-4522(96)00047-4
Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., et al.
(2004a). The role of iron and copper molecules in the neuronal vulnerability of
locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. U.S.A.
101, 9843–9848. doi: 10.1073/pnas.0403495101
Zecca, L., Youdim,M. B. H., Riederer, P., Connor, J. R., and Crichton, R. R. (2004b).
Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 5, 863–
873. doi: 10.1038/nrn1537
Conflict of Interest Statement: Mayo Clinic has a ﬁnancial interest associated with
technology used in the author’s research, which has been licensed to a commercial
entity. Mayo Clinic, but not the author, has received royalties of less than the federal
threshold for signiﬁcant ﬁnancial interest.
Received: 15 January 2014; paper pending published: 13 February 2014; accepted: 15
February 2014; published online: 03 March 2014.
Citation: Isaya G (2014) Mitochondrial iron–sulfur cluster dysfunction in neurodegen-
erative disease. Front. Pharmacol. 5:29. doi: 10.3389/fphar.2014.00029
This article was submitted to Drug Metabolism and Transport, a section of the journal
Frontiers in Pharmacology.
Copyright © 2014 Isaya. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
www.frontiersin.org March 2014 | Volume 5 | Article 29 | 7
